Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer

BACKGROUND: Docetaxel is the only FDA-approved first-line treatment for castration-resistant prostate cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumour recurrence after an initial therapeutic response with generation of multinucleated polyploid (MP) cells. Here we investigated r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Karuna, Donthamsetty, Shashi, Kaur, Ramneet, Yang, Chunhua, Gupta, Meenakshi V, Reid, Michelle D, Choi, Da Hoon, Rida, Padmashree C G, Aneja, Ritu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418452/
https://www.ncbi.nlm.nih.gov/pubmed/28334734
http://dx.doi.org/10.1038/bjc.2017.78

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418452/
https://www.ncbi.nlm.nih.gov/pubmed/28334734
http://dx.doi.org/10.1038/bjc.2017.78

Ejemplares similares